UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Lung cancer (Amsterdam, Netherlands), 2021-01, Vol.151, p.20-24

2021

Volltextzugriff (PDF)

Activation of the Keap1/Nrf2 Pathway for Neuroprotection by Electrophillic Phase II Inducers

Proceedings of the National Academy of Sciences - PNAS, 2006-01, Vol.103 (3), p.768-773

2006

Volltextzugriff (PDF)

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Annals of oncology, 2014-10, Vol.25 (10), p.1935-1940

2014

Volltextzugriff (PDF)

High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab

Annals of oncology, 2023-11, Vol.34 (11), p.1064-1065

2023

Volltextzugriff (PDF)

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Annals of oncology, 2019-12, Vol.30 (12), p.1978-1984

2019

Volltextzugriff (PDF)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

British journal of cancer, 2011-09, Vol.105 (6), p.807-813

2011

Volltextzugriff (PDF)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

British journal of cancer, 2011-05, Vol.104 (10), p.1594-1601

2011

Volltextzugriff (PDF)

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

Oncogene, 2015-01, Vol.34 (2), p.199-208

2015

Volltextzugriff (PDF)

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Oncogene, 2016-02, Vol.35 (7), p.878-886

2016

Volltextzugriff (PDF)

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Annals of oncology, 2012-06, Vol.23 (6), p.1537-1541

2012

Volltextzugriff (PDF)

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Annals of oncology, 2016-11, Vol.27 (11), p.2103-2110

2016

Volltextzugriff (PDF)

Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases

Scandinavian journal of rheumatology, 2024-07, Vol.53 (4), p.255-262

2024

Volltextzugriff (PDF)

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Annals of oncology, 2017-01, Vol.28 (1), p.136-141

2017

Volltextzugriff (PDF)

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer

Annals of oncology, 2018-03, Vol.29 (3), p.780-781

2018

Volltextzugriff (PDF)

Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab

Annals of oncology, 2017-12, Vol.28 (12), p.3106-3107

2017

Volltextzugriff (PDF)

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

Oncogene, 2011-09, Vol.30 (39), p.4097-4106

2011

Volltextzugriff (PDF)

327 INVITED Molecular Based Patient Selection in Global Clinical Trials for Non-Small Cell Lung Cancer

European journal of cancer (1990), 2011, Vol.47, p.S74-S74

Okamoto, I

2011

Volltextzugriff (PDF)

Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment

Annals of oncology, 2017-08, Vol.28 (8), p.2038-2039

2017

Volltextzugriff (PDF)

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells

British journal of cancer, 2011-07, Vol.105 (3), p.407-412

2011

Volltextzugriff (PDF)

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-02, Vol.24 (2), p.314-321

2013

Volltextzugriff (PDF)

EGFR mutation in gefitinib-responsive small-cell lung cancer

Annals of oncology, 2006-06, Vol.17 (6), p.1028-1029

2006

Volltextzugriff (PDF)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

British journal of cancer, 2008-03, Vol.98 (5), p.907-914

2008

Volltextzugriff (PDF)

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Annals of oncology, 2018-10, Vol.29, p.viii741-viii741

2018

Volltextzugriff (PDF)

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy

ESMO open, 2022-02, Vol.7 (1), p.100348-100348, Article 100348

2022

Volltextzugriff (PDF)

Combined effect of ALK and MEK inhibitors in EML4―ALK-positive non-small-cell lung cancer cells

British journal of cancer, 2012-02, Vol.106 (4), p.763-767

2012

Volltextzugriff (PDF)

1 – 25 von 78.571

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54.761)
Mit Volltextzugriff
(63.148)

Publikationsform

8 weitere anzeigen...

Weniger anzeigen...

Sprache

11 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(40.062)
Life Sciences & Biomedicine
(22.704)
Humans
(14.408)
Physical Sciences
(11.954)
Technology
(9.596)
Male
(9.328)
Female
(8.658)
Animals
(6.915)
Biological And Medical Sciences
(6.548)
Physics
(6.247)
Chemistry
(5.838)
Middle Aged
(5.386)
Exact Sciences And Technology
(5.336)
Aged
(4.725)
Adult
(4.573)
Medical Sciences
(4.505)
Materials Science
(3.860)
Engineering
(3.663)
Oncology
(3.087)
Computer Science
(2.789)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Electronic Journals Library
(30.887)
Ingenta
(23.978)
MEDLINE
(21.069)
Journals@Ovid Full Text
(13.041)
Elsevier ScienceDirect Journals Complete
(11.156)
Publisher or Other Site
(10.134)
Wiley-Blackwell Journals
(9.401)
IngentaConnect Journals
(8.510)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(8.058)
Springer Journals
(7.221)
Wiley Online Library
(5.840)
IEEE Electronic Library (IEL)
(5.236)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(5.184)
Oxford Journals
(2.883)
Nature_系列刊
(1.727)
Taylor & Francis Online
(1.689)
Taylor & Francis Journals Auto-Holdings Collection
(1.675)
Taylor & Francis
(1.594)
Ebook Central Perpetual and DDA
(1.431)
eBooks on EBSCOhost
(1.297)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Activation of the Keap1/Nrf2 Pathway for Neuroprotection by Electrophillic Phase II Inducers

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer

Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

327 INVITED Molecular Based Patient Selection in Global Clinical Trials for Non-Small Cell Lung Cancer

Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

EGFR mutation in gefitinib-responsive small-cell lung cancer

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy

Combined effect of ALK and MEK inhibitors in EML4―ALK-positive non-small-cell lung cancer cells

Suchergebnisse filtern